Verdiva Bio has secured $411 million in Series A financing, making it one of the largest funding rounds in the biotech sector since 2022.
Founders
Khurem Farooq, Jane Hughes, Tapan Maniar, Ashley Taylor, Mark Pruzanski
Company Description
Verdiva Bio is a newly launched biotech company focused on developing obesity treatments. It has licensed a portfolio of weight loss medicines from Sciwind Biosciences in China, including an oral therapy ready for Phase 2 testing.
Market
Obesity treatments
Location
China
Coinvestors
Forbion, General Atlantic, RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital